7 results
Patient risk stratification algorithm for the treatment of cancer-associated thrombosis.

Currently, edoxaban and rivaroxaban are the only
algorithm for the treatment ... of cancer-associated ... anticoagulants (DOACs ... #Anticoagulation ... #Management #Hematology
Treatment algorithm for VTE in Malignancy

(A) Suggested treatment algorithm for symptomatic and incidental DVT or PE
thrombosis in cancer ... DOAC, direct oral ... #DOAC #VTE #Malignancy ... #Anticoagulation ... #Management #Hematology
(DOAC interactions) Cancer-treatment specific inducers (↑) and inhibitors (↓)
of cytochrome p450 CYP3A4 and P-glycoprotein.

DOACs are substrates
(DOAC interactions ... ) Cancer-treatment ... DOACs are substrates ... metabolization of DOACs ... Chemotherapy #Oncology #Hematology
Leukemias Overview: ALL, CML, AML, APML, CLL

Acute leukemias > 20% blasts in the peripheral blood smear
Lymphocytes - T or B lineage ... ALL is of B-cell lineage ... Neutrophils • Immature/Myeloblasts ... lymphoid organs When Cancer ... #Leukemia #Hematology
Longterm Venous Thromboembolism Treatment Algorithm
Treat for 3 months and reassess
 • Isolated distal DVT (without cancer)
Thromboembolism Treatment ... at 3 Months • Cancer ... Thromboembolism #Treatment ... Algorithm #management #hematology ... #anticoagulation
Clotmaster Consensus 2019: Duration of Therapy for Venous Thromboembolic Disease
 • Superficial Venous Thrombosis
 • Upper
Thrombophilia • Cancer ... Bloodman #VTE #anticoagulation ... management #DVT #hematology ... #length #treatment
Essential Thrombocythemia (ET)
ET is a chronic myeloproliferative neoplasm. Most cases are related to mutations that affect
megakaryocyte lineage ... PV, MDS, CML) Treatment ... • Treatment is ... Hydroxyurea + anticoagulation ... Thrombocythemia #ET #hematology